Evidence, policy & guidance

Undersea and Hyperbaric Medicine, 2020 — Gorenstein et al. (PMID 32931666)

Randomized controlled trial showing significant improvement in oxygenation and reduced need for mechanical ventilation in severe COVID-19 patients treated with HBOT.

Cochrane Database of Systematic Reviews, 2012 (updated) — Bennett et al. (CD004609)

Cochrane systematic review of randomized controlled trials examining HBOT outcomes for acute and chronic traumatic brain injury, finding reduced risk of death.

Restorative Neurology and Neuroscience, 2015 — Hadanny et al. (doi: 10.3233/RNN-150517)

Prospective trial showing improvement in cognitive function and neuroplasticity markers following 60-session HBOT protocol in patients with chronic cognitive impairment.

Scientific Reports (Nature Portfolio), 2022 — Hadanny et al.

Randomized, sham-controlled, double-blind trial showing HBOT improved cognitive, psychiatric, fatigue, sleep and pain symptoms in post-COVID-19 patients with ongoing symptoms.

UHMS, Current Edition

The authoritative North American reference for HBOT-approved indications. The UHMS list is widely used by Canadian insurers, yet covers fewer conditions than emerging clinical evidence supports.

CUHMA — Canada's national hyperbaric medical society

Canada's national hyperbaric medical society, promoting excellence in hyperbaric and diving medicine through education and best practice guidelines.

CUHMA, 1st Edition

Official guidelines to the practice of hyperbaric medicine in Canada, including approved indications covered by provincial health plans.

Health Canada — Government of Canada

Health Canada's official information on HBOT safety, approved indications, and licensing requirements for hyperbaric chambers in Canada.

Health Justice Project, 2022

Step-by-step guide to appealing an insurance denial for hyperbaric therapy, including sample letter templates and documentation checklist for patients and advocates.

Canadian Journal of Health Law and Policy, 2021

Legal analysis examining Section 7 (life, liberty, and security of the person) arguments that may apply to patients denied access to evidence-supported therapies by provincial health plans.

SCC 35, 2005 — Applied Commentary

Analysis of how the landmark Supreme Court of Canada decision on access to private healthcare may be applied to arguments for HBOT access where public coverage is unavailable.